RDHL - RedHill Biopharma Ltd.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
6.95
-0.08 (-1.14%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close7.03
Open7.08
Bid6.10 x 900
Ask7.17 x 1000
Day's Range6.82 - 7.11
52 Week Range4.40 - 11.49
Volume41,662
Avg. Volume119,635
Market Cap183.627M
Beta (3Y Monthly)2.51
PE Ratio (TTM)N/A
EPS (TTM)-1.94
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.00
Trade prices are not sourced from all markets
  • RedHill closes $20M public offering to prep commercialization of new drug
    American City Business Journalslast month

    RedHill closes $20M public offering to prep commercialization of new drug

    RedHill Biopharma just closed on a $20 million public offering to fund the commercial launch of its drug, Talicia – which means expansion of the company's Raleigh team.

  • GlobeNewswirelast month

    RedHill Biopharma Announces Closing of $20 Million Underwritten Offering

    TEL-AVIV, Israel and RALEIGH, N.C., Dec. 11, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced the closing of its previously announced underwritten public offering for a total number of 2,857,143 American Depositary Shares (“ADSs”), each representing ten of its ordinary shares, at a public offering price of $7.00 per ADS. The Company has also granted the underwriters a 30-day option to purchase up to 428,571 additional ADSs at the public offering price.

  • GlobeNewswirelast month

    RedHill Biopharma Announces Pricing of $20 Million Underwritten Offering

    TEL-AVIV, Israel and RALEIGH, N.C., Dec. 06, 2018 -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty.

  • GlobeNewswirelast month

    RedHill Biopharma Announces Proposed Public Offering of its American Depositary Shares

    TEL-AVIV, Israel and RALEIGH, N.C., Dec. 04, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced that it intends to offer its American Depositary Shares (“ADSs”), each representing ten of its ordinary shares, in an underwritten public offering. The Company also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of ADSs offered to the public. The Company intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, to fund preparations for TALICIA® (H. pylori) commercial launch and commercialization activities, clinical development programs, including initiation of a pivotal Phase III study with RHB-204 for NTM, preparations for a second Phase III study with RHB-104 for Crohn’s disease and for acquisitions and general corporate purposes.

  • Reuterslast month

    RedHill Biopharma's antibiotic succeeds in late-stage study

    Israel-based RedHill Biopharma Ltd said on Monday its combination antibiotic met the main goal of a late-stage study testing the drug in patients with a type of bacterial infection that affects the stomach and small intestine. The drug, Talicia, eradicated the Helicobacter pylori infection in 84 percent of patients, compared with 58 percent that received a combination of two commonly used antibiotics. RedHill estimates 2.5 million patients are treated annually for H. pylori bacterial infections in the United States.

  • GlobeNewswirelast month

    RedHill Biopharma Announces Positive Top-Line Results from Confirmatory Phase 3 Study with TALICIA® for H. pylori Infection

    The ERADICATE Hp2 confirmatory Phase 3 study successfully met its primary endpoint of H. pylori eradication (84% vs. 58%) with high degree of statistical significance.

  • GlobeNewswire2 months ago

    RedHill Biopharma to Present at BMO 2018 Prescriptions for Success Healthcare Conference

    TEL-AVIV, Israel and RALEIGH, N.C., Nov. 29, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced that Mr. Dror Ben-Asher, chief executive officer of RedHill, will present a corporate overview at the BMO 2018 Prescriptions for Success Healthcare Conference on Wednesday, December 12, 2018, at 3:00 p.m. EST at the Mandarin Oriental Hotel, New York.

  • IntelGenx's NDA Resubmission for Rizaport Gets FDA Acceptance
    Zacks2 months ago

    IntelGenx's NDA Resubmission for Rizaport Gets FDA Acceptance

    The FDA accepts IntelGenx's (IGXT) NDA resubmssion for its migraine candidate Rizaport 10 mg. The stock appreciates.

  • GlobeNewswire2 months ago

    RedHill Biopharma Announces Presentation on YELIVA® (opaganib) for Multiple Myeloma at EORTC-NCI-AACR Symposium

    TEL-AVIV, Israel and RALEIGH, N.C., Nov. 14, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases and cancer, today announced a poster presentation on YELIVA® (opaganib, ABC294640)1 for multiple myeloma at the upcoming EORTC-NCI-AACR Symposium2 on Molecular Targets and Cancer Therapeutics, on Friday, November 16th in Dublin.

  • GlobeNewswire2 months ago

    RedHill Biopharma Reports Third Quarter 2018 Financial Results and Business Highlights

    Key Highlights: Top-line results from the confirmatory Phase III study with TALICIA® for H. pylori infection are on track to be announced by year-end 2018, with potential NDA.

  • GlobeNewswire2 months ago

    RedHill Biopharma to Host Third Quarter 2018 Financial Results Conference Call on November 13, 2018

    TEL-AVIV, Israel and RALEIGH, N.C., Nov. 06, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced that it will report its third quarter 2018 financial results on Tuesday, November 13, 2018. The Company will host a conference call on Tuesday, November 13, 2018 at 8:30 a.m. EST to review the financial results and business highlights.

  • GlobeNewswire3 months ago

    RedHill Biopharma to Host Analyst and Investor Webcast on TALICIA® for H. pylori infection on October 30, 2018

    Top-line results from the ERADICATE Hp2 confirmatory Phase III study expected before year-end 2018H. pylori bacterial infection affects over 50% of the adult population.

  • GlobeNewswire3 months ago

    RedHill Biopharma to Present at the BIO-Europe 2018 Conference

    TEL-AVIV, Israel and RALEIGH, N.C., Oct. 25, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced that Mr. Adi Frish, Senior VP Business Development and Licensing, will present a corporate overview at the BIO-Europe 2018 Conference, on Tuesday, November 6, 2018, at 4:15 p.m. CET, at the Bella Center in Copenhagen, Denmark.

  • GlobeNewswire3 months ago

    RedHill Biopharma Announces Final Patient Assessed in Confirmatory Phase III Study with TALICIA® for H. pylori Infection

    RedHill will host an Analyst and Investor Webcast on TALICIA® for H. pylori infection on Tuesday, October 30, 2018, at 8:30 a.m. EDTFinal patient assessed for primary endpoint,.

  • GlobeNewswire3 months ago

    RedHill Biopharma Announces Additional Data from Positive Phase III Study of RHB-104 in Crohn’s Disease at United European Gastroenterology (UEG) Week 2018

    The presentation highlighted enhanced p-values for previously reported outcomes, including the primary endpoint of clinical remission at week 26 (p=0.007) and key secondary and.

  • ACCESSWIRE5 months ago

    RedHill Biopharma Ltd. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 30, 2018 / RedHill Biopharma Ltd. (NASDAQ: RDHL ) will be discussing their earnings results in their 2018 Second Quarter Earnings to be held on August 30, 2018 at 8:30 ...

  • What's in the Offing for Keysight (KEYS) in Q3 Earnings?
    Zacks5 months ago

    What's in the Offing for Keysight (KEYS) in Q3 Earnings?

    Keysight's (KEYS) focus on launching new solutions for growth markets like 5G, IoT, next-generation wireless, high-speed datacenters and automotive & energy bodes well for its top-line.